Featured Articles

1. Why Choose A Modular Automated Approach To CAR T Manufacturing? 2/24/2026

   Get a clear, data-driven look at the biggest pressure points in cell therapy manufacturing. Explore the trends shaping today’s production challenges and where new opportunities are emerging.

2. The New Economics Of Cell Therapy Manufacturing 2/24/2026

   Cell therapy’s future hinges not just on scientific progress but on scalable manufacturing. Explore why reliability and productivity now shape viability and how modernizing operations can support growth.

3. Purification And QC Of An RNA 21‑Mer Oligonucleotide Via LC‑MS 1/27/2026

   Learn how buffer choice, gradient strategy, and pretreatment steps influence recovery, purity, and resolution when purifying a native RNA oligo, with analytical confirmation and practical guidance.

4. Scalable, Sustainable Support For Next‑Gen Primer Systems 1/27/2026

   Explore how an optimized solid‑support design enables higher synthesis scales, steadier pressures, and lower solvent use while preserving yield and purity across diverse oligonucleotide lengths.

5. Lipid Nanoparticles Boost CRISPR HDR Gene Insertion in Human T Cells 12/12/2025

   Lipid nanoparticles enable precise, non-viral gene editing in T cells to achieve high HDR efficiency and viability in scalable workflows. Explore how this approach overcomes viral vector limitations.

6. Understanding Adeno-Associated Virus Vector Impurities 11/13/2025

   AAV vectors hold promise for gene therapy, but removing product-related impurities remains a challenge. Learn how cell line development and process optimization are advancing rAAV production.

7. Cell Culture Media Demystified For Performance, Quality, And Innovation 11/13/2025

   Cell culture media isn’t one-size-fits-all. Learn how media composition, customization, and analytics can dramatically improve cell growth, productivity, and product quality for complex processes.

8. Scale-Up Of A Transient rAAV Production Process 11/3/2025

   Scalable rAAV production is achievable with a transient cell line and optimized bioreactor setup, delivering high titers and reduced impurities, now validated at 200 L scale for commercial readiness.

9. Scale-Up Of An Adherent rAAV Production Process 11/3/2025

   Fixed-bed bioreactors simplify the scale-up of viral vector production. Discover a system that bridges development and manufacturing with data confirming consistent performance across scales.

10. A Simple Method For Cell Growth Media Preparation 11/3/2025

    Explore how powder media and sterile fluid handling can reduce contamination risk and improve efficiency in viral vector production, especially for HEK293-based AAV workflows.